首页> 外文期刊>AIDS >Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial.
【24h】

Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial.

机译:长期服用睾丸激素对感染HIV的女性的影响:一项随机,安慰剂对照的试验。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: Androgen deficiency is common in HIV-infected women. We investigated the long-term effects of transdermal testosterone on body composition, bone mineral density, quality of life, and safety. DESIGN: Twenty-five HIV-infected women with free testosterone below the median (< or =3 pg/ml) of the female normal range were randomized to receive transdermal testosterone (300 microg twice weekly) or identical placebo over 18 months. RESULTS: Women demonstrated low androgen levels (1.3 +/- 0.1 pg/ml) with relatively low weight (22.8 +/- 0.6 kg/m) and low bone mineral density (-0.61 +/- 0.17 SD hip T score) at baseline. No statistically significant differences were seen between the groups at baseline. The discontinuation rate was 16% and did not differ between treatment groups (P = 0.24). Free testosterone by equilibrium dialysis increased over 18 months (7.9 +/- 1.8 vs. 0.3 +/- 0.4 pg/ml; P = 0.002, testosterone vs. placebo). Testosterone was well tolerated and did not affect lipids, liver, or safety indices. Lean mass (1.8 +/- 0.5 vs. 0.8 +/- 0.9 kg; P = 0.04) and BMI (1.6 +/- 0.4 vs. 0.8 +/- 0.6 kg/m; P = 0.03, testosterone vs. placebo) increased in response to testosterone, whereas fat mass remained unchanged. Testosterone increased bone mineral density at the hip (0.01 +/- 0.01 vs. -0.01 +/- 0.01 g/cm; P = 0.02) and trochanter (0.01 +/- 0.01 vs. -0.02 +/- 0.01 g/cm; P = 0.01, testosterone vs. placebo). Testosterone significantly improved depression indices (-6.8 +/- 2.2 vs. -1.9 +/- 3.1; P = 0.02) and problems affecting sexual function (-1.8 +/- 0.8 vs. 0.5 +/- 0.5; P = 0.01, testosterone vs. placebo). CONCLUSION: Long-term testosterone administration was well tolerated in HIV-infected women and resulted in significant improvements in body composition, bone mineral density, and quality of life indices. Further evaluation of the safety and efficacy of testosterone use among HIV-infected women is warranted.
机译:目的:雄激素缺乏症在感染艾滋病毒的女性中很常见。我们调查了经皮睾丸激素对人体成分,骨矿物质密度,生活质量和安全性的长期影响。设计:25名HIV感染的女性中游离睾丸激素低于女性正常范围的中位数(<或= 3 pg / ml),被随机分配接受透皮睾丸激素(每周两次两次,每次300微克)或18个月接受相同的安慰剂。结果:女性在基线时表现出较低的雄激素水平(1.3 +/- 0.1 pg / ml),相对较低的体重(22.8 +/- 0.6 kg / m)和较低的骨矿物质密度(-0.61 +/- 0.17 SD髋部T评分) 。基线时各组之间未见统计学显着差异。停药率为16%,治疗组之间无差异(P = 0.24)。通过平衡透析的游离睾丸激素在18个月内有所增加(7.9 +/- 1.8 vs. 0.3 +/- 0.4 pg / ml; P = 0.002,睾丸激素vs.安慰剂)。睾丸激素耐受性好,不影响血脂,肝脏或安全指数。瘦体重(1.8 +/- 0.5 vs. 0.8 +/- 0.9 kg; P = 0.04)和BMI(1.6 +/- 0.4 vs. 0.8 +/- 0.6 kg / m; P = 0.03,睾丸激素vs.安慰剂)增加响应睾丸激素,而脂肪量保持不变。睾丸激素增加了髋部的骨矿物质密度(0.01 +/- 0.01 vs. -0.01 +/- 0.01 g / cm; P = 0.02)和转子(0.01 +/- 0.01 vs. -0.02 +/- 0.01 g / cm; P = 0.01,睾丸激素对比安慰剂)。睾丸激素可显着改善抑郁指数(-6.8 +/- 2.2 vs. -1.9 +/- 3.1; P = 0.02)和影响性功能的问题(-1.8 +/- 0.8 vs. 0.5 +/- 0.5; P = 0.01,睾丸激素与安慰剂)。结论:HIV感染妇女长期服用睾丸激素具有良好的耐受性,并显着改善了身体成分,骨矿物质密度和生活质量指数。有必要进一步评估艾滋病毒感染妇女使用睾丸激素的安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号